![Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet](https://www.thelancet.com/cms/asset/480689df-d7d2-4224-9823-835cc1312b92/gr1.jpg)
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial - The Lancet
![Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK562120/bin/493434_1_En_1_Fig3_HTML.jpg)
Fig. 3, [Kaplan-Meier curves showing overall survival...]. - Brain and Human Body Modeling 2020 - NCBI Bookshelf
![Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram](https://www.researchgate.net/publication/312548097/figure/fig1/AS:616359859863564@1523963050372/Overall-survival-The-Kaplan-Meier-graph-shows-overall-survival-of-the-entire-patient.png)
Overall survival. The Kaplan-Meier graph shows overall survival of the... | Download Scientific Diagram
![Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/0b732d25-37b7-4d93-ad0b-8f60f96a958e/gr1.jpg)
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
![Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41391-020-00316-x/MediaObjects/41391_2020_316_Fig1_HTML.png)
Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England | Prostate Cancer and Prostatic Diseases
![562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer 562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer](https://ijgc.bmj.com/content/ijgc/31/Suppl_3/A251.2/F1.large.jpg)
562 Overall survival rates and progression free survival in IDS vs PDS in advanced ovarian cancer patients in the university hospitals of Leicester | International Journal of Gynecologic Cancer
![Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data](https://www.archivesofmedicalscience.com/f/pictures/99749_28bf0.jpg)
Overall survival of patients with EGFR mutation-positive non-small-cell lung cancer treated with erlotinib, gefitinib or afatinib under drug programmes in Poland – real-world data
![Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma | Future Oncology Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2021-1054/asset/images/medium/figure2.gif)
Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma | Future Oncology
![Cureus | Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience | Article Cureus | Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience | Article](https://assets.cureus.com/uploads/figure/file/56884/lightbox_96799eb01b4f11e9836e8ffceb76b5f5-Figure-1.png)
Cureus | Analysis of Overall Survival in Patients With Multiple Primary Malignancies: A Single-center Experience | Article
![Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of](https://ars.els-cdn.com/content/image/1-s2.0-S0959804914008727-fx1.jpg)
Progression free survival rate at 9 and 18 weeks predict overall survival in patients with malignant pleural mesothelioma: An individual patient pooled analysis of 10 European Organisation for Research and Treatment of
![Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology](https://www.journal-of-hepatology.eu/cms/asset/734a0236-aae1-490d-bbfe-b8cf04ab02e7/ga1.jpg)
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study - Journal of Hepatology
![Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41416-018-0061-6/MediaObjects/41416_2018_61_Fig1_HTML.jpg)